CRXT - Clarus Therapeutics GAAP EPS of -$0.24 beats by $0.06 revenue of $4.05M misses by $0.92M August, 18 2022 04:26 PM Clarus Therapeutics Holdings Inc. Clarus Therapeutics press release ( NASDAQ: CRXT ): Q2 GAAP EPS of -$0.24 beats by $0.06 . Revenue of $4.05M (+45.7% Y/Y) misses by $0.92M . Shares -4.31% . For further details see: Clarus Therapeutics GAAP EPS of -$0.24 beats by $0.06, revenue of $4.05M misses by $0.92M